FDA staff supports Gilead's Truvada as preventive med; J&J seeks growth for Xarelto;

 @FierceBiotech: Third Rock's Levin calls for teamwork in personalized medicine by @DamianFierce. Report | Follow @FierceBiotech

 @RyanMFierce: GSK's pursuit of HGSI has gone hostile as Glaxo goes directly to HGS investors with $2.6B tender offer. News | Follow @RyanMFierce

> FDA staff reviewed Gilead's ($GILD) Truvada, supporting the safety and efficacy of the HIV med as a preventive treatment for people at risk of contracting the virus. Item

> Johnson & Johnson ($JNJ) wants to get approval for its blockbuster contender Xarelto to prevent blood clots from forming in patients with heart stents. Article

> India's drug regulator and pharma outfits have been in cahoots, a study finds, highlighting concerns about lenient oversight of meds in India. Report

Pharma News

 @FiercePharma: New DSM won't make grief an illness. Panel also cuts two proposed diagnoses of psychosis and anxiety/depression--NYT. Article | Follow @FiercePharma

> Lipitor copy powers a surge in Ranbaxy sales, profits. Report

> Advisory panels take up Gilead's Truvada, then Quad. More

> Senate probes ties among narcoticsmakers, pain organizations. Story

@FierceMedDev: Covidien bought Maya Medical, the maker of a renal denervation treatment, and barely acknowledged it. Item | Follow @FierceMedDev

> Hygieia releases study results for its new hand-held insulin device. Article

> St. Jude armed with FDA approval for Ellipse ICD. Report

> Given Imaging revenue jumps overall, due to Americas PillCam sales. More

> Covidien grabs Maya Medical for $60M-plus. Item

Drug Delivery News

 @DamianFierce: The coming onslaught of blockbuster knockoffs could be a huge opportunity for drug delivery firms. News | Follow @DamianFierce

> Charge-changing nanoparticles can help kill resistant bacteria. More

> pSivida gets U.K. nod for behind-the-eye treatment. Article

> Echo's trandsdermal tech gets positive results, TV time. News

> Patent cliff could create need for novel delivery tech. Item

> MonoSol, Midatech tout positive Phase I for insulin film. Story

Biomarkers News

> Targeted therapies need cost-effective biomarkers. More

> DNA changes could predict prostate cancer relapse. Article

> 15-minute test could tag Alzheimer's. Story

> Biosignatures fingerprint tuberculosis and sarcoidosis. Story

And Finally… Details are revealed about the science involved in the diet that keeps pop idol Madonna looking young at 53. Report

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.